(Q43201113)

16 November 2017

Highly sensitive MRD tests for ALL based on the IKZF1 Δ3-6 microdeletion (English)

1 reference

16 November 2017

9

1 reference

16 November 2017

N C Venn

1

1 reference

16 November 2017

V H J van der Velden

2

1 reference

16 November 2017

M de Bie

3

1 reference

16 November 2017

E Waanders

4

1 reference

16 November 2017

J E Giles

5

1 reference

16 November 2017

T Law

6

1 reference

16 November 2017

R P Kuiper

7

1 reference

16 November 2017

V de Haas

8

1 reference

16 November 2017

M Haber

10

1 reference

16 November 2017

G M Marshall

11

1 reference

16 November 2017

Norris Md

12

1 reference

16 November 2017

J J M van Dongen

13

1 reference

16 November 2017

R Sutton

14

1 reference

16 November 2017

language of work or name

1 reference

9 December 2011

1 reference

16 November 2017

1 reference

16 November 2017

26

1 reference

16 November 2017

6

1 reference

16 November 2017

1414-1416

1 reference

Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia

16 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3377997

IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3377997

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3377997

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3377997

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3377997

Statistical methods for assessing agreement between two methods of clinical measurement

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3377997

Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3377997

Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leu

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3377997

Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3377997

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

15 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FLEU.2011.348

21 January 2018

Identifiers

DOI

10.1038/LEU.2011.348

1 reference

Dimensions Publication ID

16 November 2017

0 references

1 reference

16 November 2017

PubMed publication ID

22157735

1 reference